Join us as Josh Stahl, Chief Scientific Officer and General Manager at ArcherDX, discusses the challenges of detecting gene fusions from FFPE samples, the advantages of using Archer™ FusionPlex™ assays and how high-quality nucleic acid purification results in longer reads and higher-complexity libraries. Topics discussed will include:
This webinar is co-sponsored by Promega Corporation.
Josh was born and raised in Baltimore, MD and studied biochemistry and molecular biology at West Virginia University. After graduation, he was drawn to Colorado by the snow and mountains. He went to graduate school at the University of Colorado Boulder, where he studied small-molecular perturbation of the TLDR4/MD-2 protein interaction and its effect on morphine analgesia.
After school, he joined Thermo Fisher Scientific, developing gene modulation tools including sequencing-based, high throughput shRNA screening techniques. He joined ArcherDX when the company was in its infancy, specifically to be part of something that would make a lasting impact on healthcare. Josh enjoys skiing, off-roading, mountain biking and playing with his dog Skye.
2477 55th Street, Suite 202
Boulder, CO 80301